Physicians remain vital in obesity care, but they are not the full picture. NPs and PAs are increasingly central to how ...
Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...
UCB has announced FDA’s approval of Kygevvi (doxecitine and doxribtimine) for the treatment of adults and pediatric patients ...
Manifold Bio announced a strategic research collaboration and license agreement with Roche, aiming to apply Manifold's tissue ...
Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% ...
Recent partnership announcements in the pharma industry reflects the community’s commitment to collaborative innovation, ...
In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...
In the third entry of Pharmacuetical Executive’s premium webinar series examining the impact of President Trump’s MFN ...
Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI ...
In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...
Novartis will acquire Avidity Biosciences in a newly announced definitive merger agreement. The news follows the separation ...
In today’s Pharmaceutical Executive Daily, we cover Eli Lilly and Novo Nordisk’s plans to bring their leading weight-loss medications to the TrumpRx platform, the State of Texas’ legal move to block ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback